70978-20-0

Usage

Uses

Used in Pharmaceutical Research:
2-(4-Methoxybenzyl)-2H-tetrazole-5-carboxylic acid is used as a key intermediate in the synthesis of pharmaceuticals for its diverse pharmacological properties. 2-(4-Methoxybenzyl)-2H-tetrazole-5-carboxylic acid contributes to the development of drugs with potential antihypertensive, anticonvulsant, and antitumor activities, making it a valuable asset in medicinal chemistry.
Used in Organic Synthesis:
In the field of organic synthesis, 2-(4-Methoxybenzyl)-2H-tetrazole-5-carboxylic acid serves as a versatile building block. Its carboxylic acid moiety allows for the creation of a variety of bioactive molecules, expanding the scope of chemical compounds that can be synthesized for different applications.
Used in Drug Discovery:
2-(4-Methoxybenzyl)-2H-tetrazole-5-carboxylic acid is utilized in drug discovery processes to identify and develop new drug candidates. Its unique structure and functional groups make it a promising component in the design and synthesis of innovative therapeutic agents.
Overall, 2-(4-Methoxybenzyl)-2H-tetrazole-5-carboxylic acid holds significant potential in the realms of medicinal chemistry and drug discovery, with applications that span across various industries, including pharmaceuticals and organic synthesis.

Upstream product

• 824-94-2 p-methoxybenzyl chloride 
• 70978-33-5 potassium 2-(p-methoxybenzyl)tetrazole-5-carboxylate 

Relevant academic research and scientific papers

METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY

The present invention provides the use of a neutral endopeptidase inhibitor, in the manufacture of a medicament for the treatment, amelioration and/or prevention of contrast-induced nephropathy. The invention also relates to the use of a compound of Formula I: wherein R1, R2, R3, R5, X, A3, B1, s and n are defined herein, for the treatment, amelioration and/or prevention of contrast-induced nephropathy. The present invention further provides a combination of pharmacologically active agents for use in the treatment, amelioration and/or prevention of contrast-induced nephropathy.

METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY

The present invention provides the use of a neutral endopeptidase inhibitor, in the manufacture of a medicament for the treatment, amelioration and/or prevention of contrast-induced nephropathy. The invention also relates to the use of a compound of Formula I: wherein R1, R2, R3, R5, X, A3, B1, s and n are defined herein, for the treatment, amelioration and/or prevention of contrast-induced nephropathy. The present invention further provides a combination of pharmacologically active agents for use in the treatment, amelioration and/or prevention of contrast-induced nephropathy.

SUBSTITUTED AMINOBUTYRIC DERIVATIVES AS NEPRILYSIN INHIBITORS

The present invention provides a compound of formula (I') or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, X and n are defined herein. The invention also relates to a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

SUBSTITUTED AMINOPROPIONIC DERIVATIVES AS NEPRILYSIN INHIBITORS

The present invention provides a compound of formula I' or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, B1, X and n are defined herein. The invention also relates a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

2'Hydroxy tetrazole-5-carboxanilides and anti-allergic use thereof

New tetrazole derivatives of the general formula: STR1 [wherein R1 represents a halogen atom, a straight- or branched-chain alkyl, alkoxy, alkylthio, alkylsulphinyl, alkylsulphonyl or alkylsulphamoyl group, each such group containing from 1 to 6 carbon atoms, a dialkylsulphamoyl, dialkylamino, or dialkylcarbamoyl group (wherein the two alkyl groups may be the same or different and each contains from 1 to 4 carbon atoms), a straight- or branched-chain alkanoyl, alkoxycarbonyl, alkoxycarbonylamino, alkylcarbamoyl or alkanoylamino group containing from 2 to 6 carbon atoms, a cycloalkylcarbonyl group containing from 3 to 8 carbon atoms in the cycloalkyl moiety, or a hydroxy, formyl, nitro, trifluoromethyl, trifluoroacetyl, aryl, benzyloxycarbonylamino, amino, sulphamoyl, cyano, tetrazol-5-yl, carboxy, carbamoyl, benzyloxy, aralkanoyl or aroyl group, or a group of the formula: (wherein R2 represents a hydrogen atom or a straight- or branched-chain alkyl group containing from 1 to 5 carbon atoms, an aryl, aralkyl or trifluoromethyl group, or a cycloalkyl group containing from 3 to 8 carbon atoms, and R3 represents a hydrogen atom, or a straight- or branched-chain alkyl group containing from 1 to 6 carbon atoms optionally substituted by a phenyl group, or represents an aryl group optionally substituted by one or more substituents selected from halogen atoms and straight- or branched-chain alkyl and alkoxy groups containing from 1 to 6 carbon atoms and hydroxy, trifluoromethyl and nitro groups), and m represents zero or an integer 1, 2 or 3, the substituents R1 being the same or different when m represents 2 or 3] possess pharmacological properties, in particular properties of value in the treatment of allergic conditions.